Inhibition of AKT can restore sensitivity to cisplatin‐resistant TGCT cells by re‐localizing p21 from the cytoplasm to the nucleus (Koster et al., 2010), while PIK3CA and AKT1 mutations are exclusively found in cisplatin‐resistant tumours (Feldman et al., 2014). Here, AKT1 is linked to neoplasm.